Direct cost analysis for patients with severe asthma receiving omalizumab treatment
Open Access
- 5 September 2021
- journal article
- research article
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 4 (5) , 735-740
Abstract
Aim: The present study aims to reveal direct cost analysis of patients with severe allergic asthma receiving omalizumab treatment. Material and Methods: Twenty-two adults with severe allergic asthma who were treated with omalizumab and were routinely checked on the 16th week, 1st year, and 3rd year of treatment were included in the study. Clinical and demographic features of subjects were retrospectively documented before and after omalizumab treatment as well as pharmaceutical, emergency and hospital costs. Results: The monthly treatment cost per patient was higher during the 16th week, 1st year, and 3rd year (€411.80±190.84, €409.7±211.57, €404.2±157.30 respectively) when compared with the pre-treatment period (€107.91±48.62) (pKeywords
This publication has 28 references indexed in Scilit:
- A cost-of-illness study estimating the direct cost per asthma exacerbation in TurkeyRespiratory Medicine, 2011
- Optimal Management of Severe/Refractory AsthmaClinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2011
- The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspectiveAllergy, 2010
- Omalizumab in patients with severe persistent allergic asthma in a real-life setting in GermanyRespiratory Medicine, 2009
- Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy ModelJournal of Allergy and Clinical Immunology, 2007
- The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthmaAllergy, 2004
- Direct Medical Cost of Asthma in Ankara, TurkeyRespiration, 2004
- Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthmaJournal of Allergy and Clinical Immunology, 2004
- Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthmaCurrent Medical Research and Opinion, 2003
- Factors associated with hospital admissions and repeat emergency department visits for adults with asthmaThorax, 2000